Cost-effectiveness of HBV and HCV screening strategies - A systematic review of existing modelling techniques

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Geue, Claudia ^a   Wu, Olivia ^a   Xin, Yiqiao ^a   Heggie, Robert ^a   Hutchinson, Sharon ^b   Martin, Natasha K ^c,d   Fenwick, Elisabeth ^e   Goldberg, David ^f  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e ICON PLC   (United Kingdom)

^f HEALTH PROTECTION SCOTLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; HEPATITIS C VACCINE; INTERFERON; RIBAVIRIN;

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION TREE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE COST; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; IMMIGRANT; LIVER FUNCTION TEST; MASS IMMUNIZATION; MASS SCREENING; NEWBORN SCREENING; POLYMERASE CHAIN REACTION; PREGNANCY; PREVALENCE; PRIMARY PREVENTION; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; STATISTICAL MODEL; SYSTEMATIC REVIEW; VACCINATION; VERTICAL TRANSMISSION; COST; ECONOMIC MODEL; ECONOMICS; HEPACIVIRUS; HEPATITIS B VIRUS;

COSTS AND COST ANALYSIS; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; MASS SCREENING; MODELS, ECONOMIC;

EID: 84956600939     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145022     Document Type: Article

References (54)

1. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mãhlberger N, Wright D, et al. Long-term effectiveness and cost-effectiveness of screening for Hepatitis C virus infection. European Journal of Public Health. 2009; 19 (3): 245-53. doi: 10.1093/eurpub/ckp001 PMID: 19196737
2. Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis. 2007; 45 Suppl 4: S248-54. doi: 10.1086/522546 PMID: 18190295
3. Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013; 13: 181. doi: 10.1186/1471-2334-13-181 PMID: 23597411
4. Campbell & Cochrane Economics Methods Group. [http: //www.c-cemg.org/], Accessed June 2013.
5. Glanville J, Kaunelis D, Mensinkai S (2009). How well do search filters perform in identifying economic evaluations in MEDLINE and EMBASE. International Journal of Technology Assessment in Health Care 25 (4): 522-529. doi: 10.1017/S0266462309990523 PMID: 19845982
6. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S (2006). Good practice guideline for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 24 (4): 355-71. PMID: 16605282
7. Drummond MF, Jefferson TO, on behalf of the BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996. 313: 275-83. PMID: 8704542
8. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med. 1993; 118 (4): 298-306. PMID: 8420448
9. Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis. 52 (11): 1294-306. doi: 10.1093/cid/cir199 PMID: 21540206
10. Kim S-Y, Billah K, Lieu TA, Weinstein MC. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. Am J Prev Med. 2006; 30 (6): 498-506. PMID: 16704944
11. Mulley AG, Silverstein MD, Dienstag JL. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med. 1982; 307 (11): 644-52. PMID: 6810170
12. Ruggeri M, Cicchetti A, Gasbarrini A. The cost-effectiveness of alternative strategies against HBV in Italy. Health Policy. 102 (1): 72-80. doi: 10.1016/j.healthpol.2010.09.012 PMID: 21035229
13. Arevalo JA, Washington AE. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus.[Erratum appears in JAMA 1988 JUL 22-29;260 (4): 478]. Jama. 1988; 259 (3): 365-9. PMID: 2961895
14. Thomas IL. Cost effectiveness of antenatal hepatitis B screening and vaccination of infants. Aust N Z J Obstet Gynaecol. 1990; 30 (4): 331-5. PMID: 2150586
15. Tormans G, Van Damme P, Carrin G, Clara R, Eylenbosch W. Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus-the case of Belgium. Soc Sci Med. 1993; 37 (2): 173-81. PMID: 8351532
16. Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med. 2007; 147 (7): 460-9. PMID: 17909207
17. Rein DB, Lesesne SB, Smith BD, Weinbaum CM. Models of community-based hepatitis B surface antigen screening programs in the U.S. and their estimated outcomes and costs. Public Health Rep. 2011; 126 (4): 560-7. PMID: 21800750
18. Veldhuijzen IK, Toy M, Hahne SJM, De Wit GA, Schalm SW, de Man RA, et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology. 138 (2): 522-30. doi: 10.1053/j.gastro.2009.10.039 PMID: 19879275
19. Wong WWL, Woo G, Jenny Heathcote E, Krahn M. Cost effectiveness of screening immigrants for hepatitis B. Journal.
20. Rossi C, Schwartzman K, Oxlade O, Klein MB, Greenaway C. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. PloS one. 2013; 8 (10): e78548. doi: 10.1371/journal.pone.0078548 PMID: 24205255
21. Antonanzas F, Garuz R, Rovira J, Anton F, Trinxet C, Navas E, et al. Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain. Pharmacoeconomics. 1995; 7 (5): 428-43. PMID: 10155330
22. Kwan-Gett TS, Whitaker RC, Kemper KJ. A cost-effectiveness analysis of prevaccination testing for hepatitis B in adolescents and preadolescents. Arch Pediatr Adolesc Med. 1994; 148 (9): 915-20. PMID: 8075733
23. Zurn P, Danthine JP. [Economic evaluation of various hepatitis B vaccination Strategies in Switzerland]. Soz Praventivmed. 1998; 43 Suppl 1: S61-4. PMID: 9833269
24. Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technology Assessment. 2006; 10 (32): iii. PMID: 16948891
25. Lapane KL, Jakiche AF, Sugano D, Weng CS, Carey WD. Hepatitis C infection risk analysis: who should be screened? Comparison of multiple screening strategies based on the National Hepatitis Surveillance Program. Am J Gastroenterol. 1998; 93 (4): 591-6. PMID: 9576453
26. Loubiere S, Rotily M, Moatti J-P. Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in France. Int J Technol Assess Health Care. 2003; 19 (4): 632-45. PMID: 15095769
27. Loubiere S, Rotily M, Portal I, Bourliere M, Moatti JP. Economic evaluation of screening strategies for chronic hepatitis C. [French]. Journal.
28. Nakamura J, Terajima K, Aoyagi Y, Akazawa K. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Exp Med. 2008; 215 (1): 33-42. PMID: 18509233
29. Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average- risk adults. Am J Med. 2001; 111 (8): 614-21. PMID: 11755504
30. Stein K, Dalziel K, Walker A, Jenkins B, Round A, Royle P. Screening for hepatitis C in genito-urinary medicine clinics: a cost utility analysis. J Hepatol. 2003; 39 (5): 814-25. PMID: 14568266
31. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012; 54 (9): 1259-71. doi: 10.1093/cid/cis011 PMID: 22412061
32. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012; 55 (5): 1344-55. doi: 10.1002/ hep.25510 PMID: 22135116
33. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Annals of Internal Medicine. 2012; 156 (4): 263-70. doi: 10.7326/0003-4819-156-4-201202210-00378 PMID: 22056542
34. Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis. 2013; 56 (10): 1382-93. doi: 10.1093/cid/cit069 PMID: 23392392
35. Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS ONE. 2013; 8 (3): e58975. doi: 10.1371/journal.pone.0058975 PMID: 23533595
36. Ruggeri M, Coretti S, Gasbarrini A, Cicchetti A. Economic assessment of an anti-HCV screening program in Italy. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2013; 16 (6): 965-72.
37. Wong WW, Tu HA, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne. 2015; 187 (3): E110-21. doi: 10.1503/cmaj.140711 PMID: 25583667
38. Honeycutt AA, Harris JL, Khavjou O, Buffington J, Jones TS, Rein DB. The costs and impacts of testing for hepatitis C virus antibody in public STD clinics. Public Health Reports. 2007; 122: 55-62.
39. Josset V, Torre J-P, Tavolacci M-P, Van Rossem-Magnani V, Anselme K, Merle V, et al. Efficiency of hepatitis C virus screening strategies in general practice. Gastroenterol Clin Biol. 2004; 28 (4): 351-7. PMID: 15146150
40. Leal P, Stein K, RosenbergW. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? Journal of Medical Screening. 1999; 6 (3): 124-31. PMID: 10572842
41. Stein K, Dalziel K, Walker A, Jenkins B, Round A, Royle P. Screening for Hepatitis C in injecting drug users: a cost utility analysis. Journal of Public Health. 2004; 26 (1): 61-71. PMID: 15044577
42. Sutton AJ, Edmunds WJ, Gill ON. Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison. BMC Public Health. 2006; 6: 170. PMID: 16803622
43. Sutton AJ, Edmunds WJ, Sweeting MJ, Gill ON. The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. J Viral Hepat. 2008; 15 (11): 797-808. doi: 10.1111/j.1365-2893.2008.01008.x PMID: 18637074
44. Thompson Coon J, Castelnuovo E, Pitt M, Cramp M, Siebert U, Stein K. Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract. 2006; 23 (4): 393-406. PMID: 16799165
45. Tramarin A, Gennaro N, Compostella FA, Gallo C, Wendelaar Bonga LJ, Postma MJ. HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations. Curr Pharm Des. 2008; 14 (17): 1655-60. PMID: 18673188
46. Cipriano LE, Zaric GS, Holodniy M, Bendavid E, Owens DK, Brandeau ML. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS ONE. 2012; 7 (9): e45176. doi: 10.1371/journal.pone.0045176 PMID: 23028828
47. Schackman BR, Leff JA, Barter DM, DiLorenzo M, Feaster DJ, Metsch LR, et al. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction. 2014; 110: 129-43.
48. Jusot JF, Colin C. Cost-effectiveness analysis of strategies for hepatitis C screening in French blood recipients. European Journal of Public Health. 2001; 11 (4): 373-9. PMID: 11766476
49. Plunkett BA, Grobman WA. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis. American Journal of Obstetrics & Gynecology. 2005; 192 (4): 1153-61.
50. Urbanus AT, van Keep M, Matser AA, Rozenbaum MH, Weegink CJ, van den Hoek A, et al. Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective? PLoS ONE. 2013; 8 (8): e70319. doi: 10.1371/journal.pone.0070319 PMID: 23950920
51. Miners AH, Martin NK, Ghosh A, Hickman M, Vickerman P. Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. J Viral Hepat. 2014; 21 (9): 616-23. doi: 10.1111/jvh.12190 PMID: 24215210
52. Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis. 2012; 55 (2): 279-90. doi: 10.1093/cid/cis382 PMID: 22491339
53. Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yazdanpanah Y. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection. Gut. 2009; 58 (1): 105-10. doi: 10.1136/gut.2007.145516 PMID: 18824553
54. National Institute for Health and Clinical Excellence. (2012) Final appraisal determination-Boceprevir for the treatment of genotype 1 chronic hepatitis C.